The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache

Journal of Headache and Pain

Volumn 8, Issue 5, 2007, Pages 294-300

  Kemal Erdemoglu, Ali ^a   Varlibas, Ayhan ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Botulinum toxin type A (BoNT A); Chronic tension type headache (CTTH); Headache frequency; Headache intensity; Refractory; Treatment

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CHRONIC TENSION HEADACHE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; STATISTICAL ANALYSIS;

ADULT; ANALGESICS; BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NECK MUSCLES; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RECURRENCE; TENSION-TYPE HEADACHE; TIME; TIME FACTORS; TREATMENT OUTCOME;

EID: 36749030140     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-007-0414-7     Document Type: Article

References (33)

1. Mueller L (2002) Tension-type, the forgotten headache. How to recognize this common but undertreated condition. Postgrad Med 111:25-26, 31-32, 37-38
2. Schulman EA (2001) Overview of tension-type headache. Curr Pain Headache Rep 5:454-462
3. Cheung RTF (2000) Prevalence of migraine, tension-type headache, and other headaches in Hong Kong. Headache 40:473-479
4. Gobel H, Petersen-Braun M, Soyka D (1994) The epidemiology of headache in Germany: A nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia 14:97-106
5. Pryse-Phillips W, Findlay H, Tugwell P et al (1992) A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci 19:333-339
6. Rasmussen BK, Jensen R, Schroll M, Olesen J (1991) Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 44:1147-1157
7. Rasmussen BK, Jensen R, Olesen J (1992) Impact of headache on sickness absence and utilisation of medical services: A Danish population study. J Epidemiol Community Health 46:443-446
8. Schwartz BJ, Stewart WF, Simon D, Lipton RB (1998) Epidemiology of tension-type headache. JAMA 279:381-383
9. Jensen K, Norup M (1992) Experimental pain in human muscle induced by hypertonic saline, potassium and acidity. Cephalalgia 12:101-106
10. Rollnik JD, Karst M, Fink M, Dengler R (2001) Coping strategies in episodic and chronic tension-type headache. Headache 41:297-302
11. Holroyd KA, Stensland M, Lipchik GL et al (2000) Psychosocial correlates and impact of chronic tension-type headaches. Headache 40:3-16
12. Borodic GE, Acquadro M, Johnson EA (2001) Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert Opin Investig Drugs 10:1531-1544
13. Smuts JA, Baker MK, Smuts HM et al (1999) Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 6(suppl 4):S99-S102
14. Evers S, Vollmer-Haase J, Schwaag S et al (2004) Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24:838-843
15. Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX® Migraine Clinical Research Group (2000) Botulinum toxin type A as a migraine preventive treatment. Headache 40:445-450
16. Relja MA (1997) Treatment of tension-type headache by local injection of botulinum toxin. Euro J Neurol 4(Suppl 2):71-72
17. Relja MA (2000) Treatment of tension-type headache with botulinum toxin: 1-year follow-up. Cephalalgia 20:336
18. Ondo WG, Vuong KD, Derman HS (2004) Botulinum toxin A for chronic daily headache: A randomized, place-bo-controlled, parallel design study. Cephalalgia 2004;24:60-65
19. Schulte-Mattler WJ, Wieser T, Zierz S (1999) Treatment of tensiontype headache with botulinum toxin: A pilot study. Eur J Med Res 4:183-186
20. Schmitt WJ, Slowey E, Fravi N et al (2001) Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: A double blind, placebo-controlled trial. Headache 41:658-664
21. Rollnik JD, Tanneberger O, Schubert M et al (2000) Treatment of tension-type headache with botulinum toxin A: A double-blind, placebo-controlled study. Headache 2000; 40:300-305
22. Silberstein SD, Göbel H, Jensen R et al (2006) Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: A multicentre, double-blind, randomized, placebo-controlled, parallel-group study Cephalalgia 26:790-800
23. Burch CM, Kokoska MS, Glaser DA, Hollenbeak CS (2001) Treatment of frontal tension headaches with botulinum toxin A. Cephalalgia 21:486-491
24. Relja MA, Telarovic S. Botulinum toxin in tension-type headache (2004) J Neurol 251(Suppl)1/12-1/14
25. Mennini FS, Fioravanti L, Piasini L et al (2004) A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache. J Headache Pain 5:188-191
26. Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: A five-year long experience. J Headache Pain 7: 407-412
27. Mathew N, Frishberg BM, Gawel M et al (2005) Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache 45:293-307
28. Jensen R (2003) Peripheral and central mechanisms in tension-type headache: An update. Cephalalgia 23(Suppl. 1): 49-52
29. Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache 43(suppl 1):9-15
30. Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:125-133
31. Durham PL, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35-42; discussion 42-43
32. Oshinsky ML, Pozo-Rosich P, Luo J et al (2004) Botulinum toxin type A blocks sensitization of neurons in the trigeminal nucleus candalis. Cephalalgia 24:781
33. Mathew N (2006) The Prophylactic Treatment of Chronic Daily Headache Headache 46:1552-1564